Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From...

Area of Science:

• Oncology
• Immunology
• Infectious Diseases

Background:

• T-cell engagers represent a significant advancement in cancer therapy.
• Understanding infectious complications is crucial for managing patients on these novel treatments.

Purpose of the Study:

• To investigate the incidence of infectious complications in patients treated with T-cell engagers.
• To identify risk factors associated with these infections.

Main Methods:

• Retrospective analysis of 181 patients undergoing T-cell engager therapy.
• Data collection on patient demographics, disease type, treatment history, and infectious events.

Main Results:

• Infectious complications were observed in patients with hematological malignancies and those heavily pre-treated.
• The mortality rate due to infections was 2.8%.
• Concomitant use of corticosteroids or tocilizumab did not significantly alter infection incidence.

Conclusions:

• T-cell engager therapy is associated with infectious risks, especially in vulnerable patient populations.
• Risk stratification and monitoring are essential for patients undergoing T-cell engager treatment.
• Further research may explore specific preventative strategies against infections in this cohort.